Cure Accelerator

Tracking every breakthrough from lab to patient. Science should not move slowly.

156
Breakthroughs Tracked
84
Active Trials
47
Barriers Identified
7
Disease Categories

Cure Pipeline

42Discovery
28Preclinical
19Phase I
14Phase II
8Phase III
3FDA Review
5Approved

How Close Are We? -- AI-Estimated Research Completeness

Diabetes
70%

GLP-1 agonists transforming treatment; multiple approved therapies

HIV
60%

Functional cure trials active; long-acting injectable PrEP approved

Heart Disease
55%

GLP-1 cardiovascular benefits; PCSK9 inhibitors reducing events

Cancer
45%

CAR-T, mRNA vaccines, checkpoint inhibitors advancing rapidly

Parkinson's
30%

Alpha-synuclein antibodies in Phase 2; gene therapy emerging

Alzheimer's
25%

Lecanemab approved 2023; amyloid hypothesis partially validated

ALS
15%

Tofersen approved for SOD1-ALS; antisense oligonucleotides promising

Clinical Trial Tracker

TrialPhaseStatusETA
KEYNOTE-B36Phase 3Active2027 Q2
CRISPR-SCD-001Phase 2Enrolling2026 Q4
PSIL-MDD-301Phase 3Active2027 Q1
mRNA-1283Phase 3Active2026 Q3
ALZ-801-302Phase 3Enrolling2028 Q1
CART-DLBCL-5Phase 2Active2027 Q3

Tracked Research

mRNA Vaccine Technology

5/5
Immunology / Molecular BiologyDeployed — ExpandingVerified

Messenger RNA vaccines instruct cells to produce proteins that trigger immune responses, enabling rapid vaccine development. After proving transformative agains...

Key Findings
COVID-19 vaccines developed in under 11 months (unprecedented speed)
Personalized cancer vaccines in Phase 2 trials showing tumor regression

CRISPR Gene Therapy

4/5
Genetics / Gene EditingFirst Approved TreatmentHigh

CRISPR-Cas9 gene editing enables precise modification of DNA sequences. The first CRISPR therapy (Casgevy by Vertex/CRISPR Therapeutics) was approved in 2023 fo...

Key Findings
Casgevy approved UK (Nov 2023) and FDA (Dec 2023) — first CRISPR therapy
Base editing corrects single-letter mutations without cutting DNA

Psychedelic-Assisted Therapy

3/5
Psychiatry / NeurosciencePhase 3 TrialsModerate

Clinical research demonstrates that psilocybin, MDMA, and ketamine, administered in controlled therapeutic settings, can produce rapid and durable improvements ...

Key Findings
Psilocybin shows 4x remission rate vs. placebo in treatment-resistant depression
MDMA-assisted therapy: 71% of PTSD patients no longer met diagnostic criteria

CAR-T Cell Therapy

4/5
Oncology / ImmunotherapyApproved — ExpandingHigh

Chimeric Antigen Receptor T-cell therapy reprograms a patient's own immune cells to recognize and destroy cancer. FDA-approved for certain blood cancers since 2...

Key Findings
6 FDA-approved CAR-T products for blood cancers
Complete remission rates of 50-90% in some leukemias and lymphomas

GLP-1 Receptor Agonists Beyond Diabetes

5/5
Endocrinology / CardiologyExpanding — NewVerified

Originally developed for Type 2 diabetes, GLP-1 receptor agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) are showing remarkable effects beyond blood sugar ...

Key Findings
SELECT trial: 20% cardiovascular event reduction in non-diabetic obese patients
Tirzepatide achieves 22.5% body weight loss in SURMOUNT-1 trial